
Invicro Scientists Published in Science Translational Medicine
Invicro LLC, a Konica Minolta company and a leading provider of imaging biomarkers, core lab services and software for research and drug development, announces that the paper “In vivo Detection of Cerebral Tau Pathology in Long-term Survivors of Traumatic Brain Injury1” has been published in Science Translational Medicine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190904005895/en/
Invicro scientists published in Science Translational Medicine (Graphic: Business Wire)
Invicro London scientists, Doctors Alex Whittington, Jan Passchier and Roger Gunn, are co-authors of this revolutionary study that uses positron emission tomography (PET) to understand tau pathology in traumatic brain injuries (TBI), years after they occur. The results illustrate that tau PET is an encouraging approach for measurement of progressive neurodegeneration associated with tauopathy following TBI.
“It was exciting to be part of this groundbreaking study with Dr. Nikos Gorgoraptis and Prof. David Sharp which shows that Tau PET imaging is an important biomarker for TBI and CTE,” stated Dr. Roger Gunn, EVP of Quantitative Data Sciences for Invicro and Professor of Molecular NeuroImaging at Imperial College London. “The advanced Tau analytics that were developed as part of this work further complement Invicro’s leading TauIQ analytics platform in Neurodegeneration.”
TBI can lead to life-long chronic neurodegeneration, including the possibility of dementia. The publication examines how the use of Flortaucipir ([18F]AV-1451, [18F]T807), a PET radioligand for tau, enables the examination of tau pathology in vivo in subjects who are long-term survivors of brain injuries. Flortaucipir has demonstrated potent and specific non-displaceable binding to tau neurofibrillary tangles in both post-mortem human brain tissue and brain scans of subjects with Alzheimer Disease. This study elegantly shows how tau signals can now also be detected in subjects suffering from brain injuries.
“Advanced analytical methods were required to produce these exciting findings and we are delighted that this work has been recognized by Science Translational Medicine, a journal that is known for publishing impactful and high-quality research,” stated Dr. Alex Whittington, PET and MRI Neuro-Imaging Analyst for Invicro.
Established in October 2009 by American Association for The Advancement of Science, Science Translational Medicine is a weekly journal focused on translational medicine and clinical research on human diseases. The journal seeks research that demonstrate significant and innovative progress toward the prevention, diagnosis, or treatment of disease in the field of translational medicine. Science Translational Medicine published “In vivo Detection of Cerebral Tau Pathology in Long-term Survivors of Traumatic Brain Injury” on 4 September 2019 at 2 P.M. EST.
“Tau Imaging in neurodegenerative diseases, specifically TBI, is making significant strides,” stated Dr. Jan Passchier, EVP Global Head Laboratories and Clinics for Invicro. “The success of the research presented in this paper is undoubtedly a result of the combination of academic excellence of our esteemed collaborators and the operational and scientific strength Invicro has been able to bring to bear. I look forward to continuing our joint efforts in this important area in order to support disease understanding and enable development and objective testing of potential therapeutic strategies.”
1. “In vivo Detection of Cerebral Tau Pathology in Long-term Survivors of Traumatic Brain Injury," Authors: Nikos Gorgoraptis, Lucia M. Li, Alex Whittington, Karl A. Zimmerman, Linda M. Maclean, Claire McLeod, Ewan Ross, Amanda Heslegrave, Henrik Zetterberg, Jan Passchier, Paul M. Matthews, Roger N. Gunn, Tom M. McMillan, David J. Sharp
About Invicro
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017. Now as part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®, has inspired a strong and growing presence in the pre-clinical to late-phase clinical markets. For more information, visit www.invicro.com.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190904005895/en/
Contact information
Amanda Harrell
VP, Global Marketing
media@invicro.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo